image
Healthcare - Biotechnology - NASDAQ - US
$ 0.5848
1.04 %
$ 54.1 M
Market Cap
-0.51
P/E
1. INTRINSIC VALUE

This DCF valuation model was last updated on Jun, 21, 2025.

The intrinsic value of one VRCA stock under the worst case scenario is HIDDEN Compared to the current market price of 0.585 USD, Verrica Pharmaceuticals Inc. is HIDDEN

This DCF valuation model was last updated on Jun, 21, 2025.

The intrinsic value of one VRCA stock under the base case scenario is HIDDEN Compared to the current market price of 0.585 USD, Verrica Pharmaceuticals Inc. is HIDDEN

This DCF valuation model was last updated on Jun, 21, 2025.

The intrinsic value of one VRCA stock under the best case scenario is HIDDEN Compared to the current market price of 0.585 USD, Verrica Pharmaceuticals Inc. is HIDDEN

2. FUNDAMENTAL ANALYSIS

Price Chart VRCA

image
$0.8$0.8$0.7$0.7$0.7$0.7$0.6$0.6$0.6$0.6$0.5$0.5$0.5$0.5$0.4$0.4Jan '25Jan '2515 Jan15 JanFeb '25Feb '2515 Feb15 FebMar '25Mar '2515 Mar15 MarApr '25Apr '2515 Apr15 AprMay '25May '2515 May15 MayJun '25Jun '2515 Jun15 Jun
FINANCIALS
7.57 M REVENUE
47.66%
-65.9 M OPERATING INCOME
-0.24%
-76.6 M NET INCOME
-14.31%
-60.9 M OPERATING CASH FLOW
-57.94%
-19 K INVESTING CASH FLOW
94.75%
37.7 M FINANCING CASH FLOW
-49.16%
3.44 M REVENUE
899.71%
-8.13 M OPERATING INCOME
28.75%
-9.74 M NET INCOME
39.87%
-12.7 M OPERATING CASH FLOW
21.08%
0 INVESTING CASH FLOW
0.00%
-4.06 M FINANCING CASH FLOW
-10.29%
Balance Sheet Verrica Pharmaceuticals Inc.
image
Current Assets 51.2 M
Cash & Short-Term Investments 46.3 M
Receivables 77 K
Other Current Assets 4.77 M
Non-Current Assets 2.96 M
Long-Term Investments 0
PP&E 2.58 M
Other Non-Current Assets 376 K
85.58 %8.82 %4.76 %Total Assets$54.1m
Current Liabilities 29 M
Accounts Payable 1.9 M
Short-Term Debt 14.3 M
Other Current Liabilities 12.8 M
Non-Current Liabilities 35 M
Long-Term Debt 32.3 M
Other Non-Current Liabilities 2.65 M
2.96 %22.30 %20.07 %50.53 %4.14 %Total Liabilities$64.0m
EFFICIENCY
Earnings Waterfall Verrica Pharmaceuticals Inc.
image
Revenue 7.57 M
Cost Of Revenue 1.85 M
Gross Profit 5.71 M
Operating Expenses 71.6 M
Operating Income -65.9 M
Other Expenses 10.7 M
Net Income -76.6 M
10m10m00(10m)(10m)(20m)(20m)(30m)(30m)(40m)(40m)(50m)(50m)(60m)(60m)(70m)(70m)(80m)(80m)8m(2m)6m(72m)(66m)(11m)(77m)RevenueRevenueCost Of RevenueCost Of RevenueGross ProfitGross ProfitOperating ExpensesOperating ExpensesOperating IncomeOperating IncomeOther ExpensesOther ExpensesNet IncomeNet Income
RATIOS
75.51% GROSS MARGIN
75.51%
-871.25% OPERATING MARGIN
-871.25%
-1012.15% NET MARGIN
-1012.15%
776.66% ROE
776.66%
-141.46% ROA
-141.46%
-167.33% ROIC
-167.33%
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis Verrica Pharmaceuticals Inc.
image
00(10m)(10m)(20m)(20m)(30m)(30m)(40m)(40m)(50m)(50m)(60m)(60m)(70m)(70m)201720172018201820192019202020202021202120222022202320232024202420252025
Net Income -76.6 M
Depreciation & Amortization 1.27 M
Capital Expenditures -27 K
Stock-Based Compensation 7.16 M
Change in Working Capital 2.03 M
Others 3.45 M
Free Cash Flow -61 M
3. WALL STREET ANALYSTS ESTIMATES
Wall Street Analysts Price Targets Verrica Pharmaceuticals Inc.
image
Wall Street analysts predict an average 1-year price target for VRCA of $12 , with forecasts ranging from a low of $10 to a high of $14 .
VRCA Lowest Price Target Wall Street Target
10 USD 1609.99%
VRCA Average Price Target Wall Street Target
12 USD 1951.98%
VRCA Highest Price Target Wall Street Target
14 USD 2293.98%
Price
Max Price Target
Min Price Target
Average Price Target
1414121210108866442200Aug '24Aug '24Oct '24Oct '24Nov '24Nov '2420252025Feb '25Feb '25Apr '25Apr '25Jun '25Jun '25Jul '25Jul '25Aug '25Aug '25Oct '25Oct '25Nov '25Nov '2520262026Feb '26Feb '26Apr '26Apr '26Jun '26Jun '26Jul '26Jul '26
4. DIVIDEND ANALYSIS
5. COMPETITION
slide 2 of 16
6. Ownership
Insider Ownership Verrica Pharmaceuticals Inc.
image
Sold
0-3 MONTHS
0 USD 0
3-6 MONTHS
2.8 K USD 1
6-9 MONTHS
0 USD 0
9-12 MONTHS
1.08 M USD 5
Bought
0 USD 0
0-3 MONTHS
0 USD 0
3-6 MONTHS
50.9 M USD 3
6-9 MONTHS
0 USD 0
9-12 MONTHS
7. News
Verrica Pharmaceuticals to Participate in the Jefferies Global Healthcare Conference in New York WEST CHESTER, Pa., May 28, 2025 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica” or “the Company”) (Nasdaq: VRCA), a dermatology therapeutics company developing medications for skin diseases requiring medical interventions, today announced that Jayson Rieger, PhD, MBA, President and Chief Executive Officer of Verrica Pharmaceuticals, will present at the Jefferies Global Healthcare Conference in New York City. globenewswire.com - 1 month ago
Verrica Pharmaceuticals, Inc. (VRCA) Q1 2025 Corporate Update Conference Call Verrica Pharmaceuticals, Inc. (NASDAQ:VRCA ) Q1 2025 Corporate Update Conference Call May 13, 2025 4:30 PM ET Company Participants Kevin Gardner - Managing Director LifeSci Advisors Jayson Rieger - President and CEO John Kirby - Interim CFO Conference Call Participants Stacy Ku - TD Cowen Gregory Renza - RBC Capital Markets Serge Belanger - Needham and Company Kemp Dolliver - Brookline Capital Markets Operator Good evening, ladies and gentlemen, and welcome to the Verrica Pharmaceuticals' First Quarter 2025 Corporate Update Conference Call. At this time, all participants are in a listen-only mode. seekingalpha.com - 1 month ago
Verrica Pharmaceuticals Inc. (VRCA) Reports Q1 Loss, Tops Revenue Estimates Verrica Pharmaceuticals Inc. (VRCA) came out with a quarterly loss of $0.10 per share versus the Zacks Consensus Estimate of a loss of $0.14. This compares to loss of $0.38 per share a year ago. zacks.com - 1 month ago
Verrica Pharmaceuticals Reports Quarterly 2025 Financial Results – Company reports $3.4 million in YCANTH revenue, reflective of increasing demand, following the dispensing of more than 10,000 applicator units in the quarter, the most in company history and a 16.7% growth over Q4'24 – – Late-stage pipeline continues to advance with completion of end-of-Phase 2 meeting with Food and Drug Administration for VP-315, Verrica's candidate for basal cell carcinoma, and continued advancement towards initiation of global Phase 3 program in common warts (VP-102/YCANTH) with partner Torii Pharmaceutical – – Conference call scheduled for today at 4:30 pm ET – WEST CHESTER, Pa., May 13, 2025 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica”) (Nasdaq: VRCA), a dermatology therapeutics company developing and selling medications for skin diseases requiring medical interventions, today announced financial results for the quarter ended March 31, 2025. globenewswire.com - 1 month ago
Verrica Pharmaceuticals to Report First Quarter 2025 Financial Results and Provide a Corporate Update on May 13, 2025 WEST CHESTER, Pa., May 07, 2025 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica” or “the Company”) (Nasdaq: VRCA), a dermatology therapeutics company developing medications for skin diseases requiring medical interventions, today announced that it will host a conference call and live webcast at 4:30 p.m. globenewswire.com - 1 month ago
Verrica Pharmaceuticals to Participate in the Citizens Life Sciences Conference in New York WEST CHESTER, Pa., April 30, 2025 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica” or “the Company”) (Nasdaq: VRCA), a dermatology therapeutics company developing medications for skin diseases requiring medical interventions, today announced that Jayson Rieger, PhD, MBA, President and Chief Executive Officer of Verrica Pharmaceuticals, will present at the Citizens Life Sciences Conference in New York City. globenewswire.com - 2 months ago
Verrica Pharmaceuticals Appoints Gavin Corcoran, M.D. to its Board of Directors WEST CHESTER, Pa., April 02, 2025 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica” or the “Company”) (Nasdaq: VRCA), a dermatology therapeutics company developing medications for skin diseases requiring medical interventions, today announced the appointment of Gavin Corcoran, M.D. globenewswire.com - 3 months ago
Here's Why Verrica Pharmaceuticals (VRCA) Is a Great 'Buy the Bottom' Stock Now Verrica Pharmaceuticals (VRCA) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong agreement among Wall Street analysts in revising earnings estimates higher enhances the stock's potential for a turnaround in the near term. zacks.com - 3 months ago
Verrica Pharmaceuticals to Participate in the 24th Annual Needham Virtual Healthcare Conference WEST CHESTER, Pa., March 31, 2025 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica” or “the Company”) (Nasdaq: VRCA), a dermatology therapeutics company developing medications for skin diseases requiring medical interventions, today announced that Jayson Rieger, PhD, MBA, President and Chief Executive Officer of Verrica Pharmaceuticals, will participate in a fireside chat at the 24th Annual Needham Virtual Healthcare Conference. globenewswire.com - 3 months ago
Verrica Pharmaceuticals Appoints Noah L. Rosenberg, M.D. WEST CHESTER, Pa., March 26, 2025 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica” or the “Company”) (Nasdaq: VRCA), a dermatology therapeutics company developing medications for skin diseases requiring medical interventions, today announced the appointment of Noah L. Rosenberg, M.D., as Chief Medical Officer. globenewswire.com - 3 months ago
Verrica Pharmaceuticals, Inc. (VRCA) Q4 2024 Earnings Conference Call Transcript Verrica Pharmaceuticals, Inc. (NASDAQ:VRCA ) Q4 2024 Earnings Conference Call March 10, 2025 4:30 PM ET Company Participants John Fraunces - Director, Corporate Communications, LifeSci Advisors, IR Jayson Rieger - President and CEO John Kirby - Interim CFO Conference Call Participants Stacy Ku - TD Cowen Gregory Renza - RBC Capital Markets Kemp Dolliver - Brookline Capital Markets Operator Good evening, ladies and gentlemen, and welcome to the Verrica Pharmaceuticals' Fourth Quarter and Full Year 2024 Corporate Update Conference Call. At this time, all participants are in a listen-only mode. seekingalpha.com - 3 months ago
Verrica Pharmaceuticals Inc. (VRCA) Reports Q4 Loss, Lags Revenue Estimates Verrica Pharmaceuticals Inc. (VRCA) came out with a quarterly loss of $0.24 per share versus the Zacks Consensus Estimate of a loss of $0.25. This compares to loss of $0.48 per share a year ago. zacks.com - 3 months ago
8. Profile Summary

Verrica Pharmaceuticals Inc. VRCA

image
COUNTRY US
INDUSTRY Biotechnology
MARKET CAP $ 54.1 M
Dividend Yield 0.00%
Description Verrica Pharmaceuticals Inc., a dermatology therapeutics company, develops and commercializes treatments for people with skin diseases in the United States. The company's lead product candidate includes VP-102 for the treatment of molluscum contagiosum; that has completed Phase II clinical trial for the treatment of external genital warts; and which is in Phase II clinical trial for treating common warts. It is also developing cantharidin-based product candidate, VP-103 for treating plantar warts. The company has a license and collaboration agreement with Torii Pharmaceutical Co., Ltd. for the development and commercialization of its product candidates for the treatment of molluscum contagiosum and common warts in Japan, including VP-102; and a license agreement with Lytix Biopharma AS to develop and commercialize LTX-315 for dermatological oncology indications. Verrica Pharmaceuticals Inc. was incorporated in 2013 and is headquartered in West Chester, Pennsylvania.
Contact 44 West Gay Street, West Chester, PA, 19380 https://www.verrica.com
IPO Date June 15, 2018
Employees 71
Officers Mr. David Zawitz Chief Operating Officer Dr. Bradley J. Catalone MBA, Ph.D. Head of Drug Development Mr. John J. Kirby CPA Interim Chief Financial Officer Mr. Eugene Scavola Executive Vice President of Technical Operations Dr. Noah L. Rosenberg M.D. Chief Medical Officer Dr. Jayson M. Rieger M.B.A., Ph.D. President, Chief Executive Officer & Director